Home NEWS AND MEDIA

Clinical | NeuExcell Therapeutics Reports Encouraging Clinical Results with In Situ Conversion Therapy for Malignant Glioma

05 Dec 2025

Related news

11 / Jun 2025

NeuExcell Therapeutics Announces First Dosing of NXL-001 in a Patient with Ten Years of Alzheimer's Disease
Learn more
08 / Mar 2025

NeuExcell Therapeutics Initiates First-in-Human Clinical Trial of NXL-001 to Treat Alzheimer's Disease
Learn more
21 / Mar 2024

NeuExcell Therapeutics Announces Successful Dosing of First Patient by NeuroD1 Gene Therapy
Learn more